Chest
-
DVT/PE PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: In this retrospective study, we compare the meterological parameters between the patients who had risk factors and idiopatic pulmonary embolism (PE) patients. We looked for seasonal variations in the incidence of idiopathic PE and a relationship with atmospheric pressure, humidity, or temperature. ⋯ The following authors have nothing to disclose: Tuba Inal, Ceyda Anar, Ipek Unsal, Gülru Polat, Hüseyin HalilçolarNo Product/Research Disclosure Information.
-
Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: With the burden of COPD increasing, new treatment strategies to optimize pharmacotherapy include combination therapies with complementary modes of action. This phase 3 trial evaluated efficacy and safety of fixed-dose combinations of aclidinium, a long-acting anticholinergic indicated for maintenance treatment of COPD-associated bronchospasm, and formoterol, a long-acting β2-agonist, in moderate to severe COPD patients. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: Dr. D'Urzo has received research, consulting and lecturing fees from GlaxoSmithKline, Sepracor, Schering Plough, Altana, Methapharma, AstraZeneca, ONO pharma, Merck Canada, Forest Laboratories, Novartis Canada/USA, Boehringer Ingelheim (Canada) Ltd, Pfizer Canada, SkyePharma, and KOS Pharmaceuticals. Stephen Rennard: Consultant fee, speaker bureau, advisory committee, etc.: Stephen Rennard has received honoraria for lectures from AARC, Almirall, Am Col Osteopathic Physicians, Asan Medical Center, American Thoracic Society, California Society of Allergy, CME Incite, COPD Foundation, Creative Educational Concepts, Dey, Duke University, Forest, France Foundation, HSC Medical Education, Information TV, Lung Association, Novartis (Horsham, Nycomed, Otsuka, PeerVoice, Pfizer, Shaw Science, University of Washington, University of Alabama Birmingham, VA Sioux Falls., Consultant fee, speaker bureau, advisory committee, etc.: Stephen Rennard has also received honorarium for consulting with the following: ABIM, Able Associates, Adelphi Research, Align2Acton, Almirall/Prescott, APT Pharma/Britnall, Astra-Zeneca, American Thoracic Society Beilenson, Boehringer Ingelheim, Boehringer Ingelheim (ACCP), BoomCom, Britnall and Nicolini, Capital Research, Chiesi, Clarus Acuity, CommonHealth, Complete Medical Group, Consult Complete, COPDForum, DataMonitor, Decision Resources, Dunn Group, Easton Associates, Equinox, and Forest., Consultant fee, speaker bureau, advisory committee, etc.: (continued) Frankel Group, Fulcrum, Gerson Lehman, Globe Life Sciences, Guidepoint, Health Advanced, Hoffman LaRoche, Informed, Insyght, KOL Connection, Leerink Swan, M. Pankove, McKinsey, MDRxFinancial, Medimmune, Merck, Novartis, Nycomed, Oriel, Osterman, Peal, Penn Technology, Pennside, Pfizer, PharmaVentures, Pharmaxis, Prescott, Price Waterhouse, Propagate, Pulmonary Reviews, Pulmatrix, Reckner Associates, Recruiting Resource, Roche, Sankyo, Schering, and Schlesinger., Consultant fee, speaker bureau, advisory committee, etc.: (continued) Scimed, Smith Research, Sudler and Hennessey, Summer Street Research, Talecris, Think Equity, UBC, Uptake Medical, Vantage Point Management. Victor Mergel: Employee: Victor Mergel is an employee of Forest Research Institute, Inc. Esther Garcia Gil: Employee: Esther Garcia Gil is an employee of Almirall S.A. Anne Leselbaum: Employee: Anne Leselbaum is an employee of Almirall S.A. Cynthia Caracta: Employee: C. Caracta is an employee of Forest Research Institute, Inc. , Shareholder: C. Caracta is a stockowner and has received stock options from Forest Laboratories, Inc.Aclidinium bromide (Tudorzo/Pressair, Eklira/Genuair, Breo/Ellipta) is approved for the maintenance treatment of COPD-associated bronchspasm. The fixed-dose combination of aclidinium bromide/formoterol fumarate is being developed, but not yet approved, for its commercial use for the treatment of COPD.
-
Respiratory Infections PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Chest imaging 4-8 weeks following diagnosis of community-acquired pneumonia (CAP) is a routine and historically recommended practice. There is insufficient data to support this practice and the most recent recommendations are mute on the subject. This study examines the real-world practice of chest imaging following CAP; the rate persistent radiographic abnormalities; and the association of persistent abnormalities with clinical risk factors and subsequent non-malignant and malignant pulmonary diseases. ⋯ The following authors have nothing to disclose: Luke Surry, Michael Morris, William HannahNo Product/Research Disclosure Information.
-
Pleural Disease/Pleural Effusion PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To find biochemical parameters in pleural fluid, that may exceed the performance of Light criteria to discriminate transudates and exudates. Assess whether the clinical diagnosis exceeds or not biochemical parameters of pleural fluid to differentiate transudates and exudates. ⋯ The following authors have nothing to disclose: Carolina Gotera, Deisy Barrios Barreto, Patricia Lazo Meneses, Rosa Mirambeaux Villalona, Carolina Jurkojc Mohremberger, Esteban Perez Rodriguez, Salvador Diaz Lobato, Sagrario Mayoralas AlisesNo Product/Research Disclosure Information.
-
Lung Cancer Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Lung cancer remains the leading cause of cancer deaths wordlwide. There is a limited data evaluating overall five years lung cancer survival. The aim of this study is to describe the characteristics of our patients with lung cancer and the five years survival rate in our hospital. ⋯ The following authors have nothing to disclose: Rosa Maria Ortiz Comino, Noemi Burgos Guadix, Rosa Lina De los Santos de Lopez, Ana Dolores Romero Ortiz, Manuel De VegaNo Product/Research Disclosure Information.